Antifungal prophylaxis for invasive mycoses in high risk patients

Current Opinion in Infectious Diseases

Volumn 19, Issue 6, 2006, Pages 571-576

  Ullmann, Andrew J ^a   Cornely, Oliver A ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Acute myeloid leukemia; Graft versus host disease; Hematopoietic stem cell transplantation; Invasive fungal disease; Prophylaxis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLOSIS; CLINICAL TRIAL; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; MYCOSIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES;

EID: 33750506091     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3280108e45     Document Type: Article

References (61)

1. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32:686-693.
2. Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43:e29-e38. This was a large European study on various amphotericin B formulations and its association with hospital length of stay, toxicity and mortality.
3. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
4. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37:173-180.
5. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23:608-615.
6. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-366.
7. Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230-3246.
8. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101:3365-3372.
9. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57:317-325. This was a large randomized study on itraconazole in patients with profound neutropenia.
10. Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998; 12:1338-1343.
11. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131:22-28. The authors conducted a meta-analysis on itraconazole antifungal prophylaxis.
12. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 21:4615-4626.
13. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50:143-147. This describes the second published randomized prophylaxis study with an echinocandin.
14. Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17:1306-1312. This was an interesting study on a low-dose prophylaxis strategy with a polyene.
15. Cornely OA, Maertens J, Winston D, et al. Standard azole (FLU/ITZ) therapy for prophylaxis of invasive fungal infections (IFIs) among high-risk neutropenic patients: results of a randomized, multicenter trial [abstract]. In: 47th Annual Meeting of the American Society of Hematology; 9-13 December 2005; Atlanta. Washington, DC: American Society of Hematology; 2005. Abstract 1844.
16. Cornely OA, Maertens J, Winston D, et al. Posaconazole vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome: impact on mortality [abstract]. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy 16-19 December 2005; Washington, DC. Washington DC: American Society for Microbiology. 2005. Abstract 722b.
17. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96:497-503.
18. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19:801-808.
19. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-1466.
20. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116:475-482.
21. Goldberg SP, Baddley JW, Aaron MF, et al. Fungal infections in ventricular assist devices. ASAIO J 2000; 46:S37-S40.
22. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
23. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-1552.
24. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-2061.
25. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28:322-330.
26. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49:1-7.
27. Wingard JR, Beals SU, Santos GW, et al. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987; 2:175-181.
28. Saugier-Veber P, Devergie A, Sulahian A, et al. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant 1993; 12:121-124.
29. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917.
30. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-833.
31. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138:705-713.
32. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527-1533.
33. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557-1559.
34. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-1416.
35. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease [abstract]. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2005; Washington, DC. Washington DC: American Society for Microbiology; 2005. Abstract 716.
36. Tollemar J, Ericzon BG, Holmberg K, et al. The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant Proc 1990; 22:242-244.
37. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:729-737.
38. Cruciani M, Mengoli C, Malena M, et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12:850-858. This is a retrospective analysis on antifungal prophylaxis in liver transplant recipients.
39. Shah T, Lai WK, Gow P, et al. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis 2005; 7:126-132. This describes a study on the antifungal prophylaxis with low-dose amphotericin B in liver transplant recipients.
40. Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005; 11:656-662. This was a comparative study on antifungal prophylaxis by risk assessment in liver transplant recipients.
41. Castroagudin JF, Ponton C, Bustamante M, et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 2005; 37:3965-3967. The authors conducted a comparative study on antifungal prophylaxis in high-risk liver transplant recipients.
42. Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multicenter prospective observational study. Am J Transplant 2006; 6:386-391. This was a comparative study on antifungal prophylaxis by risk assessment in liver transplant recipients.
43. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75:2023-2029.
44. Ruffini E, Baldi S, Rapellino M, et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:181-190.
45. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 2005; 24:2148-2152. This was a prospective prophylaxis trial in lung transplant recipients with a very low IFD incidence.
46. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72:545-548.
47. Drew RH, Dodds AE, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77:232-237.
48. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States. Clin Infect Dis 2001; 33:641-647.
49. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38:311-320.
50. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-548.
51. Garbino J, Lew DP, Romand JA, et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-1717.
52. Jacobs S, Price Evans DA, Tariq M, et al. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med 2003; 31:1938-1946.
53. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-746.
54. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-952.
55. Girmenia C, Moleti ML, Micozzi A, et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 2005; 43:5395-5396. This is a case report on breakthrough fungal infections during caspofungin exposure.
56. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-1359. The authors present case reports on breakthrough zygomycetes infections during antifungal exposure.
57. Lionakis MS, Kontoyiannis DP. Sinus zygomycosis in a patient receiving voriconazole prophylaxis. Br J Haematol 2005; 129:2. Case reports on breakthrough zygomycetes infections during voriconazole exposure.
58. Manuel DG, Kwong K, Tanuseputro P, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ 2006; 332:1419.
59. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-1250. This describes an important study on a preemptive therapy strategy.
60. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-1151.
61. Dodds Ashley ES, Alexander BD. Posaconazole. Drugs Today (Barc) 2005; 41:393-400.